Rock Springs Capital HUM Position
Exited3-Fund ConvergenceRock Springs Capital exited their position in HUMANA INC (HUM) in Q4 2024, after holding the stock for 8 quarters.
The position was first reported in Q1 2023 and has been tracked across 8 quarterly 13F filings.
HUM is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About HUMANA INC
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Full company profile →Short Interest
5.6%
3.7 days to cover
Rock Springs Capital HUM Position History
Frequently Asked Questions
Does Rock Springs Capital own HUM?
No. Rock Springs Capital exited their position in HUMANA INC (HUM) in Q4 2024. They previously held the stock for 8 quarters.
How many hedge funds own HUM?
3 specialist biotech hedge funds currently hold HUM, including OrbiMed Advisors, Redmile Group, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy HUM?
Rock Springs Capital's position in HUM was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's HUM position increasing or decreasing?
Rock Springs Capital completely exited their HUM position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
HUMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →